Forbion analysis on European biotech landscape published in Nature Biotechnology
in company news
Revealing large differences in the startup scene across Europe and highlighting the underlying causal factors
Naarden, The Netherlands, and Munich, Germany, April 2, 2019 Forbion, a leading European life sciences venture capital firm, today announces that its analysis on the European biotech start-up landscape is being published in Nature Biotechnology.
The study shows large differences in biotechnology startup formation among the various European nations. Factors contributing positively to a successful biotechnology start-up ecosystem include a robust, government-funded science base, but the analysis also emphasizes the need for strength in both financial (i.e.venture capital) and human capital, and for biomedical patent activity. https://www.nature.com/articles/s41587-019-0076-4
The article follows a series of earlier publications by Forbion in Nature biotechnology, including Venturing Across the Atlantic, (https://www.nature.com/articles/nbt.3712) Acquiring Orphans (https://www.nature.com/articles/nbt.2836), and Building for big pharma (https://www.nature.com/bioent/2013/130301/full/bioe.2013.3.html). These articles represent primary research on topics that are of interest to biotech entrepreneurs, investors and policy makers. Forbion believes that fundamental science drives biomedical innovation, and aspires to help scientists and biotech entrepreneurs to advance science into the development of drugs that have a genuine impact on the future of medicine.